Kezar Life Sciences, Inc. (KZR) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated Mar 20, 2026
Current Price
$7.29
Price Target
$6.00
Target Range
$5.00 — $7.00
Analyst Rating
Hold
Forward P/E—
Trailing P/E-1.0x
Forward PEG—
Implied Growth+23.0%
Median Target$6.00
Analyst Spread33.3%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$5
-31.4%
Consensus
$6
-17.7%
Bull Case
$7
-4.0%
KZR Price Target Analysis
Updated June 13, 2026As of June 13, 2026, Kezar Life Sciences, Inc. (KZR) has a Wall Street consensus price target of $6.00, based on estimates from 7 covering analysts. With the stock currently trading at $7.29, this represents a potential downside of -17.7%. The company has a market capitalization of $54M.
Analyst price targets range from a low of $5.00 to a high of $7.00, representing a 33% spread in expectations. The median target of $6.00 aligns closely with the consensus average.
The current analyst consensus rating is Hold, with 2 analysts rating the stock as a Buy or Strong Buy,5 rating it Hold, and 0 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, KZR trades at a trailing P/E of -1.0x. Analysts expect EPS to grow +23.0% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+107.1%
Avg Forward P/E45.8x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 IMVTImmunovant, Inc. | $6.9B | $33.62 | $43.67 | +29.9% | Buy | — | 23 |
 ARQTArcutis Biotherapeutics, Inc. | $3.0B | $24.38 | $34.00 | +39.5% | Buy | 122.5x | 12 |
 PRAXPraxis Precision Medicines, Inc. | $7.7B | $266.54 | $607.15 | +127.8% | Buy | — | 16 |
 TGTXTG Therapeutics, Inc. | $7.6B | $49.52 | $54.50 | +10.1% | Buy | 35.9x | 13 |
 CABACabaletta Bio, Inc. | $491M | $3.01 | $16.33 | +442.5% | Buy | — | 12 |
 RCUSArcus Biosciences, Inc. | $2.4B | $23.80 | $31.00 | +30.3% | Buy | — | 18 |
 HRMYHarmony Biosciences Holdings, Inc. | $2.0B | $34.46 | $43.00 | +24.8% | Buy | 10.1x | 13 |
 VKTXViking Therapeutics, Inc. | $3.3B | $28.75 | $93.60 | +225.6% | Buy | — | 24 |
 ACADACADIA Pharmaceuticals Inc. | $3.6B | $21.09 | $34.78 | +64.9% | Buy | 54.2x | 37 |
 INVAInnoviva, Inc. | $1.7B | $22.74 | $40.00 | +75.9% | Buy | 6.4x | 10 |
Upside Potential Comparison
CABAVKTXPRAXINVAACADARQTRCUSIMVTWhat if you invested $1,000 in KZR 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in KZR be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs KZR Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationKZR vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowKZR — Frequently Asked Questions
Quick answers to the most common questions about buying KZR stock.
What is the KZR stock price target for 2026?
KZR's consensus price target is $6, -17.7% below the current price of $7.29. The 7 analysts tracking KZR see downside risk at present valuations.
Is KZR a buy, sell, or hold?
KZR has a consensus rating of "Hold" based on 7 Wall Street analysts. The rating breakdown is mixed, with 5 Hold ratings making up the largest segment. The consensus 12-month price target of $6 implies -17.7% downside from current levels.
Is KZR stock overvalued or undervalued?
KZR's current price is $7.29 with a consensus target of $6 (-17.7% implied move). Analyst estimates suggest the stock is overvalued at current levels.
How high can KZR stock go?
The most bullish Wall Street analyst has a price target of $7 for KZR, while the most conservative target is $5. The consensus of $6 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover KZR stock?
KZR is moderately covered, with 7 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 5 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the KZR stock forecast?
The 12-month KZR stock forecast based on 7 Wall Street analysts shows a consensus price target of $6, with estimates ranging from $5 (bear case) to $7 (bull case). The median consensus rating is "Hold".
Should I buy KZR stock?
Analysts are cautious on KZR, with 0 Sell ratings and a price target of $6 (-17.7% from current price). The "Hold" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do KZR price targets vary so much?
KZR analyst price targets range from $5 to $7, a 33% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $6 consensus represents the middle ground.